With the continued impact of COVID-19 on businesses, organisations and individuals, boohoo co-founders and entrepreneurs Richard Hughes and Mahmud Kamani established Medusa19 with the objective of rapidly building a point-of-care medical diagnostics business, ensuring employee safety and business continuity, ‘Rebuilding Confidence’ in businesses and the economy.

As founder-shareholders of boohoo group plc, Richard and Mahmud have extensive experience in e-commerce, supply chains, marketing and e-fulfilment – all on a global basis. Richard is also founder of Crawford Healthcare Limited and Zeus Capital Limited. 

Currently, Medusa 19 offers the Rapid Saliva Protein Test (RSPT), a new fifteen-minute saliva-based test that indicates immune response to SARS-CoV-2, the virus underlying COVID-19.  The test is CE marked to 98/79/EC, registered with the MHRA.

Medusa 19 Logo

Rapid Saliva Protein Test

The Rapid Saliva Protein Test (RSPT), from Medusa 19, provides results on the spot in 15 minutes. It is a lateral flow saliva test to indicate the immune response to infection particularly in patients whom do not know they have an active SARS-CoV-2 infection and have no specific symptoms.

The Rapid Saliva Protein Test (RSPT) is a simple, non-invasive, on the spot test indicating the immune response to infection from SARS-CoV-2, the virus underlying COVID-19.

It is a lateral flow test requiring a simple saliva sample, a comfortable and non-invasive collection process, providing rapid results within 15 minutes.

Developed in the UK and Spain, the test indicates a user’s immune response to SARS-CoV-2.

Relative sensitivity of 92%, relative specificity of 98% and 97% accuracy.

Avacta Life Sciences Antigen Saliva Test – COMING SOON

Medusa 19 has entered into a distribution agreement with Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, for its COVID-19 rapid antigen saliva test that is currently under development. 

This agreement provides Medusa 19 with exclusive distribution rights to consumers and non-exclusive distribution rights to businesses.

The test is being developed to use a sample of saliva to indicate whether an individual has the COVID-19 infection and is intended to provide a result within minutes.

See more on the Avacta site or via our news section.

Saturn Pass – COMING SOON

Medusa 19 is also working with Saturn Pass, who are developing a Digital Health Passport App for iOS and Android.  This will include:-

  • Full Facial recognition and Identity Document Scanning
  • Unique Home and Workplace test verification capability using Computer Vision
  • Legal declaration with approved e-signing
  • Patent Pending